ALLGENESIS BIOTHERAPEUTICS INC.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Allgenesis focuses on developing innovative ophthalmic therapies targeting both retinal and anterior segment diseases. Its pipeline includes AG-73305, a dual-action anti-VEGF and disintegrin molecule for diabetic macular edema and age-related macular dege
The content above was translated by Ai
Founded Year
2014
Unified Business No.
54681545
Status
Active
Number of Employees
0
Total Paid-in
Capital
912,600,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Allgenesis is a privately owned, clinical stage, biopharmaceutical company situated in Taipei City, Taiwan.We strive to find solutions for major diseases of the eye affecting the vision of millions of people worldwide.Our mission is to establish a world-renowned biopharmaceutical business in Taiwan to invent and develop novel medicines for the global market.
The content above was translated by Ai
